Jun Liang

Jun Liang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XHXiaotao Huang
Xiaotao Huang
QLQiaodan Liu
Qiaodan Liu
GZGuihua Zhong
Guihua Zhong
YPYingpeng Peng
Yingpeng Peng
YLYe Liu
Ye Liu
ZLZhigang Liu
Zhigang Liu
Background: Neoadjuvant programmed death receptor-1 (PD-1) inhibitors have drawn increasing attention in locally advanced head and neck squamous cell carcinoma (HNSCC). In this study, we investigated the safety and efficacy of gemcitabine and cisplatin (GP), combined with a PD-1 inhibitor, in patients with locally advanced HNSCC. Materials and methods: A total of 23 eligible patients were administered two cycles of toripalimab and GP followed by surgical resection. The primary endpoints were safety, treatment-related adverse events (TRAEs), and non-operation delay rates. The secondary endpoints consisted of pathological complete response (pCR) rate, major pathological response (MPR) rate, objective response rate (ORR), and R0 resection rate. Results: The incidence of TRAEs from grades 1 to 4 was 43.5%, 34.8%, 13.0%, and 8.7%, respectively. Grade 3/4 TRAEs included neutropenia, fatigue, hyperglycemia, nausea and vomiting, decreased appetite, rash, and diarrhea. No treatment-related surgical delay was observed. The radiographic response rates were 5.0% (CR), 40.0% (PR), and 55.0% (SD). The ORR reached 45.0%. Eighteen patients underwent successful surgical resection. The R0 resection rate was 100%. The pathological response rates were 16.7% (pCR), 27.8% (MPR, two of five near-pCR), 16.7% (PPR), and 38.8% (NPR). CD4, CD8, CD20, and CD38 expression in the tumors significantly increased after neoadjuvant chemotherapy. The increase in CD20 levels after neoadjuvant treatment in patients with pCR/MPR was significantly higher than in patients with PPR/NPR. Conclusion: Triweekly neoadjuvant toripalimab-GP is feasible and achieves promising pCR and MPR rates in patients with resectable locally advanced HNSCC. Trial registration: Chinese clinical trial registry, ChiCTR2100043743, Registered 27 Febrary 2021- Retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=120570

14 April 2020 in Oral Diseases
Verified
Journal Article
Closed access
PDF file
QKQianying Kong
Qianying Kong
YLYancan Liang
Yancan Liang
QHQifen He
Qifen He
YYYingying You
Yingying You
LWLifen Wu
Lifen Wu
JLJun Liang
Jun Liang

9 January 2021 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
ZDZhaoming Deng
Zhaoming Deng
WLWei Liao
Wei Liao
WWWei Wei
Wei Wei
GZGuihua Zhong
Guihua Zhong
CHChao He
Chao He
ZLZhigang Liu
Zhigang Liu
Background: Oral squamous cell carcinoma (OSCC) has been one of the most malignant cancers in head and neck region. Anlotinib is a tyrosine kinase inhibitor targeting several receptors such as vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. Here we investigated whether Anlotinib have any antitumor effect on oral cancer and tried to explore and explain the possible mechanism. Methods: Data from The Cancer Genome Atlas and the Gene Expression Omnibus and Gene Expression Omnibus database was collected to analyze the relationship between the expression of vascular epithelial growth factor receptor 2 and the overall survival rate of OSCC. Oral cancer cell lines Cal-27 and SCC-25 were cultured to conduct all the experiments. In vitro experiments such as CCK-8, colony formation, cell cycle assay and cell apoptosis assay were conducted to detect cell proliferation ability and the change of cell phase and apoptosis. Proteins concerning cell cycle and cell apoptosis were visualized via western blot. α-Tubulin were visualized via immunofluorescence to detect cells undergoing mitotic catastrophe. Results: Higher expression of VEGFR-2 was significantly related to poorer prognosis. Experiment in vitro demonstrated that cell proliferation was significantly inhibited(p < 0.05) after Anlotinib administration and G2/M arrest and apoptosis were both detected in both cell lines. Cycle-related proteins promoting cell cycle progression and proteins related to cell survival were downregulated in Anlotinib group compared to the control group. Cell-death-related biomarker and phosphorylated histone 3 were upregulated in expression in Anlotinib group. Abnormal spindle apparatus was observed in cells undergoing mitotic catastrophe. Conclusions: Anlotinib could exert an antitumor effect on oral cancer cell lines via apoptotic pathway and mitotic catastrophe pattern, presenting a promising potential therapy for patients with OSCC.

1 April 2018 in Journal of Cranio-Maxillofacial Surgery
Verified
Journal Article
Closed access
LLLizhong Liang
Lizhong Liang
HLHaiji Luo
Haiji Luo
QHQifen He
Qifen He
YYYingying You
Yingying You
YFYunping Fan
Yunping Fan
JLJun Liang
Jun Liang

26 October 2024 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
SHSongkai Huang
Songkai Huang
JZJunwei Zhang
Junwei Zhang
YQYu Qiao
Yu Qiao
JPJanak Lal Pathak
Janak Lal Pathak
RZRui Zou
Rui Zou
KOKexiong Ouyang
Kexiong Ouyang
Background: CHRDL1 belongs to a novel class of mRNA molecules. Nonetheless, the specific biological functions and underlying mechanisms of CHRDL1 in oral squamous cell carcinoma (OSCC) remain largely unexplored. Methods: RT-qPCR and immunohistochemical staining were employed to assess the mRNA and protein expression levels of the MED29 gene in clinical samples of OSCC. Additionally, RT-qPCR and Western Blot analyses were conducted to investigate the mRNA and protein expression levels of the MED29 gene specifically in OSCC. The impact of MED29 on epithelial-mesenchymal transition (EMT), invasion, and migration of OSCC was evaluated through scratch assay, transwell assay, and immunofluorescence staining. Furthermore, wound healing assay and Transwell assay were utilized to examine whether CHRDL1 influences the malignant behavior of OSCC by modulating MED29 in vitro. The regulatory role of CHRDL1 on MED29 was further elucidated in vivo through a tail vein lung metastasis model in nude mice. Results: MED29 expression was elevated in tumor tissues of OSCC patients compared with adjacent cancer tissues. Moreover, in CAL27 and SCC25 cell lines, MED29 was upregulated and associated with increased cell migration and invasion abilities. Overexpression of MED29 facilitated EMT in OSCC cell lines, whereas knockdown of MED29 impeded EMT, resulting in diminished cell migration and invasion capacities. CHRDL1 exerted inhibitory effects on the expression of MED29, thereby suppressing EMT progression and consequently restraining the invasion and migration of OSCC cells. Furthermore, CHRDL1 mediated the inhibition of migration of OSCC cell lines to the OSCC through its regulation of MED29. Conclusions: MED29 facilitated the epithelial-mesenchymal transition process in OSCC, thereby promoting migration and invasion. On the other hand, CHRDL1 exerted inhibitory effects on the invasion and metastasis of OSCC by suppressing MED29 through the inhibition of the MAPK signaling pathway.

1 August 2019 in Annals of Translational Medicine
Verified
Journal Article
Closed access
PDF file
JLJun Liang
Jun Liang
ZDZhaoming Deng
Zhaoming Deng
HGHan Gao
Han Gao
Stafne’s bone defect (SBD) or Stafne’s bone cavity (SBC) is an uncommon bony defect occurred especially only at the lingual cortex of mandible. Clinically, patients with SBD are usually asymptomatic. In most cases, the defect is observed accidentally via X-ray panorama during other dental treatments. Here we presented a female with SBD and we reviewed relevant literatures on SBD, summarized the clinical characteristic and radiographic features with our experiences.